Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectives
Authors:
- Toshiyuki MiyataTMToshiyuki Miyata
- 1 January 2007
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 120 (1) , 1-10
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Biomedical Innovation
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 64 references indexed in Scilit:
- Population variation in VKORC1 haplotype structureJournal of Thrombosis and Haemostasis, 2006
- Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast AsiansThe Journal of Pharmacology and Experimental Therapeutics, 2005
- A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding RiskPLOS Medicine, 2005
- A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceJournal of Thrombosis and Haemostasis, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- PharmacogeneticsClinical Pharmacokinetics, 2001
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Flexible induction dose regimen for warfarin and prediction of maintenance dose.BMJ, 1984